| DB ID | MyCo_2398 |
| Title | Prospective evaluation of a combination of fungal biomarkers for the diagnosis of invasive fungal disease in high-risk haematology patients |
| Year | 2018 |
| PMID | 29577474 |
| Fungal Diseases involved | Invasive fungal infection |
| Disease | Aspergillosis (Aspergillus Infection) |
| Associated Medical Condition | High- |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | The study was approved by the Regional Ethics Committee in Göteborg (Reg nr 433- |
| Site of Infection | Unspecified |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Sweden |
| Cohort | In total, 135 patients were monitored once to twice weekly for serum (1- |
| Cohort No. | 135 |
| Age Group | -18 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Sub Technique | ELISA |
| Technique | Immunoassay |
| Analysis Method | ELISA Based |
| ELISA kits | Glucatell® assay kit (Ass. Cape Cod, MA, USA) |
| Assay Data | None |
| Validation Techniques used | FDA Approved -Platelia Aspergillus Ag ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
